APKON - National Pandemic Cohort Network – Monkeypox PlatformAnalysis of pathophysiology and pathology of Monkeypox Virus (MPV), including chronic morbidity

• Conditions: B04; Monkeypox

• Registration Number: DRKS00029147
• Lead Sponsor: niversitätsklinikum Frankfurt, Medizinische Klinik 2

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-08-17
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting withdrawn before recruiting started
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Age = 18 years,
Willingness to participate in the study,
Symptomatic MPV infection (e.g. rash, fever, or other signs and symptoms associated with MPV infection and without other more plausible cause),
Consent within 14 days of symptom onset,
Positive MPV PCR from blood or skin sample (swab or biopsy)

Exclusion Criteria

Any condition that prohibits supplemental blood-sampling beyond routine blood drawing

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Following the principle of NAPKON as a data and biospecimen collection platform for the Netzwerk Universitätsmedizin NUM, a specific primary endpoint was not included. The primary objective of the NAPKON Monkeypox Platform is to provide a comprehensive and harmonized collection of data and biosamples for researchers from national consortia and for participation in international research collaborations for the purpose of studying MPV Infection.